First European Conference on SRS/SBRT and IG-IMRT Held in Milan

Sunnyvale, California (ots/PRNewswire) -

Accuray Incorporated [http://www.accuray.com ] , today announced
highlights from the First European Conference on stereotactic
radiosurgery/stereotactic body radiation therapy (SRS/SBRT) and
image-guided intensity-modulated radiation therapy (IG-IMRT), hosted
in partnership with the Istituto Europeo di Oncologia Milano and the
Universita degli studi di Milano, held in Milan, Italy on February
22-23, 2013.

The conference "Radiation Oncology: can we still treat without image
guidance?" was attended by more than 400 healthcare professionals,
including radiation oncologists, medical physicists and hospital
administrators from 32 countries. Outcomes of recent research in
areas such as central nervous system (CNS), head and neck, breast,
lung, gastrointestinal (GI), pelvis, total marrow irradiation (TMI)
and pediatrics were presented.

The independent Scientific Committee, led by Prof. Roberto Orecchia
(Istituto Europeo di Oncologia Milano, Italy) and Prof. Eric Lartigau
(Centre Oscar Lambret, Lille, France), focused on new developments in
the field and developed an educational event to discuss the need of
image guidance for a variety of clinical indications in modern
radiation therapy. "Daily image guidance is crucial for all
high-precision treatments, also for palliative treatments" said Prof.
Eric Lartigau.

"The TomoTherapy(R) System provides an automatic process that makes
our daily work easy" said Prof. Dirk Verellen, UZ Brussel.

Prof. Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of
Rotterdam, said "Additionally, dose to the healthy tissue can be
strongly reduced using optimal and numerous non-coplanar beams when
treating prostate cancer" comparing non-coplanar treatments to
coplanar treatments.

"There are non-adaptive and real-time adaptive solutions, but the
only solution that adapts for target motion in real-time, available
clinically, is the CyberKnife(R) System", added Dr. Iciar Santa
Olalla.

About Accuray

Accuray Incorporated , is a radiation oncology company that develops,
manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live
longer, better lives. The Company's leading-edge technologies deliver
the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement Statements made in this press release that are
not statements of historical fact are forward-looking statements and
are subject to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this
press release relate, but are not limited, to clinical applications,
clinical results, patient outcomes, and the Company's leadership
position in radiation oncology innovation. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including risks
detailed from time to time under the heading "Risk Factors" in the
company's report on Form 10-K filed on September 10, 2012, as updated
in our Form 10-Qs filed on November 8, 2012 & February 6, 2013, and
as updated periodically by our other filings. Forward-looking
statements speak only as of the date the statements are made and are
based on information available to the Company at the time those
statements are made and/or management's good faith belief as of that
time with respect to future events. The Company assumes no obligation
to update forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors affecting
forward-looking information, except to the extent required by
applicable securities laws. Accordingly, investors should not place
undue reliance on any forward-looking statements.

Contacts

Anja Kleber
Marketing Director
Tel +33(0)1-55-23-20-20
[email protected]

Sophie Baumont
Edelman Paris
Tel +33(0)1-56-69-75-94
[email protected]

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print